Ligand Pharmaceuticals | LGND - Selling And Administration Expenses


Ligand Pharmaceuticals reported $29.12M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
Agenus USD 6.21M 4.34M Mar/2026
Amgen USD 1.72B 134M Jun/2026
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 46.63M 4.88M Jun/2026
Baxter International USD 735M 7M Jun/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Eli Lilly USD 3.43B 496M Jun/2026
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Enviri Corporation USD 104.1M 10.81M Dec/2025
Gilead Sciences USD 1.52B 70M Jun/2026
GlaxoSmithKline GBP 2.16B 39M Sep/2026
Glaxosmithkline GBP 2.12B 1.44B Mar/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Insmed USD 247.47M 208K Jun/2026
Intrexon USD 10.31M 41K Jun/2024
Ionis Pharmaceuticals USD 130.07M 20.92M Jun/2026
Karyopharm Therapeutics USD 10.42M 861K Mar/2026
Ligand Pharmaceuticals USD 29.12M 8.29M Jun/2026
MacroGenics USD 9.71M 1.77M Mar/2026
Merck USD 2.89B 219M Jun/2026
Pacira USD 91.81M 7.93M Jun/2026
Pfizer USD 3.41B 496M Jun/2026
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Veracyte USD 55.71M 4.87M Jun/2026